2k sports

2k sports Only the coldest of hearts won’t empathize with Michael Andretti, who has been sidelined from his namesake motorsports organization and won’t have any role with the the Formula 1 program he spent the last four years desperately trying to launch. His effort to get a program partnered with General Motors into F1 was approved last week, roughly a month after Andretti stepped aside from leading his race teams. F1’s decision to expand its grid for Cadillac F1 came amidst a federal antitrust investigation into why Liberty Media refused to admit Andretti Global as an 11th team — and after Andretti partners Dan Towriss and Mark Walter took controlling interest of the effort. “The Cadillac F1 Team is made up of a strong group of people that have worked tirelessly to build an American works team,” Andretti posted on social media. “I’m very proud of the hard work they have put in and congratulate all involved on this momentous next step. I will be cheering for you!” While he will have no role with the F1 team, it is unclear what his regular involvement will be with his IndyCar team. His famous father, 1978 F1 champion Mario Andretti, will be on the board of the F1 team and an ambassador. What changed F1’s position on Andretti — an application it basically mocked in its January denial — is not known. Few have said much beyond noting GM’s increased commitment to take a larger role beyond engine supplier. Mohammed Ben Sulayem, the president of F1’s governing body, had championed the GM bid from the start and Andretti’s application was the only one of seven to receive approval from the FIA. In an interview with The Associated Press, he called F1’s decision to finally allow the GM team a spot in the sport “a win for all of motorsports” but also sympathized with Michael Andretti. “I feel he should be proud because he’s the founder who started this thing with his partners,” Ben Sulayem said. “We did the proper due process, we never favored anyone, and it is only because his application ticked all the boxes that the FIA approved it. Michael is a lovely person and I do not feel this was personal against Michael Andretti. “The other teams? For them, it was about the money. They don’t want the money to go from split between 10 teams to split between 11 teams,” he added. “But it was only a matter of time before General Motors was going to be approved and I feel it is incorrect to say it happened because Michael stepped aside. What did Michael do? Why would people not want him? Because he spoke publicly? He didn’t break any rules. He didn’t abuse anyone. If people want to see it as personal, it is up to them. He doesn’t annoy me.” What likely did annoy F1 and Liberty Media, its commercial rights holder, was the Justice Department investigation. Liberty announced it was under investigation this summer, not long after Mario Andretti visited Washington to discuss the F1 snub with lawmakers. The FBI was allegedly at last month’s Las Vegas Grand Prix and Ben Sulayem confirmed to AP he was interviewed by federal investigators. “It is the department that protects the interest of the United States and the FIA has nothing to hide,” Ben Sulayem said. “I was proud to speak to them and they were very polite and understanding. I wanted this to be cleared: I wanted GM in F1 because it is good for business.” F1 currently has just one American team, owned by California businessman Gene Haas, despite a series-high three races in the United States. Should the Cadillac F1 team make it to the grid in 2026 as scheduled, there will be two American teams and Ford will officially join Red Bull that season as a technical partner. This Andretti-less F1 effort will be led by TWG Global, the investment company founded by Walter, who as CEO of Guggenheim Partners is the controlling owner of the Los Angeles Dodgers and Premier League club Chelsea, and Towriss, who became involved in motorsports initially as a sponsor for Andretti and took an ownership role in Andretti Global in 2022. Towriss is now the majority owner of the Andretti race teams and work on the F1 team will continue in Andretti’s Indiana shop, its recently opened satellite factory in Silverstone and GM’s facilities in North Carolina and Michigan. Towriss is the CEO of TWG Global’s motorsports arm. There is no indication who the drivers will be for the F1 team, although Valtteri Bottas indicated last weekend he’d like to be considered and the original Andretti effort targeted current IndyCar driver Colton Herta, who is sponsored by Towriss’ company, Gainbridge. Get local news delivered to your inbox!James, Quigley and Hayes combine for 59 points as No. 20 NC State women beat Coastal Carolina 89-68

TORONTO — Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company’s strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations. As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company’s technology. Mr. Kirk is currently Founder and Editor-In-Chief of TravelPulse Canada and TravelPulse Quebec based in Toronto, Ontario, Canada. He has been in the travel industry for over 25 years, working in the tour operator and aviation space with Porter Airlines, where he founded PorterEscapes.com, and Thomas Cook North America as SVP E-Commerce and Retail Distribution. He was responsible for some of Canada’s legendary retail brands such as, The Last-Minute Club, Bel Air Travel, Avion Travel, and Algonquin Travel, covering on-line, store front, and call centre, with annual retail sales in excess of over 500 million dollars generated by a retail sales force of over 350 travel advisors across Canada. John is known throughout North America as a leading travel expert and has deep routed relationships crossing all spectrums, from front line sellers of travel to government dignitaries. “ ,” commented Mr. Kirk who will begin his Advisory Board activities effective immediately. Tony Di Benedetto, CEO of Syntheia, commented: “ ” For more information and to read customer testimonials, visit . Syntheia is an artificial intelligence technology company which is developing and commercializing proprietary algorithms to deliver human-like conversations. Our SaaS platform offers conversational AI solutions for both enterprise and small-medium business customers globally. For further information, please contact: Tony Di Benedetto Chief Executive Officer Tel: (844) 796-8434Friday's Mega Millions drawing is worth an estimated $1.15 billion, one of the game's top jackpots

Into the earthLAS VEGAS (AP) — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. Read this article for free: Already have an account? To continue reading, please subscribe: * LAS VEGAS (AP) — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. Read unlimited articles for free today: Already have an account? LAS VEGAS (AP) — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. “As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It’s an honor for General Motors and Cadillac to join the world’s premier racing series, and we’re committed to competing with passion and integrity to elevate the sport for race fans around the world,” GM President Mark Reuss said. “This is a global stage for us to demonstrate GM’s engineering expertise and technology leadership at an entirely new level.” The approval ends years of wrangling that launched a U.S. Justice Department investigation into why Colorado-based Liberty Media, the commercial rights holder of F1, would not approve the team initially started by Michael Andretti. Andretti in September stepped aside from leading his namesake organization, so the 11th team will be called Cadillac F1 and be run by new Andretti Global majority owners Dan Towriss and Mark Walter. The team will use Ferrari engines its first two years until GM has a Cadillac engine built for competition in time for the 2028 season. Towriss is the the CEO and president of Group 1001 and entered motorsports via Andretti’s IndyCar team when he signed on financial savings platform Gainbridge as a sponsor. Towriss is now a major part of the motorsports scene with ownership stakes in both Spire Motorsports’ NASCAR team and Wayne Taylor Racing’s sports car team. Walter is the chief executive of financial services firm Guggenheim Partners and the controlling owner of both the World Series champion Los Angeles Dodgers and Premier League club Chelsea. “We’re excited to partner with General Motors in bringing a dynamic presence to Formula 1,” Towriss said. “Together, we’re assembling a world-class team that will embody American innovation and deliver unforgettable moments to race fans around the world.’’ Mario Andretti, the 1978 F1 world champion, will have an ambassador role with Cadillac F1. But his son, Michael, will have no official position with the organization now that he has scaled back his involvement with Andretti Global. The approval has been in works for weeks but was held until after last weekend’s Las Vegas Grand Prix to not overshadow the showcase event of the Liberty Media portfolio. Max Verstappen won his fourth consecutive championship in Saturday night’s race, the third and final stop in the United States for the top motorsports series in the world. Grid expansion in F1 is both infrequent and often unsuccessful. Four teams were granted entries in 2010 that should have pushed the grid to 13 teams and 26 cars for the first time since 1995. One team never made it to the grid and the other three had vanished by 2017. There is only one American team on the current F1 grid — owned by California businessman Gene Haas — but it is not particularly competitive and does not field American drivers. Andretti’s dream was to field a truly American team with American drivers. The fight to add this team has been going on for three-plus years and F1 initially denied the application despite approval from F1 sanctioning body FIA. The existing 10 teams, who have no voice in the matter, also largely opposed expansion because of the dilution in prize money and the billions of dollars they’ve already invested in the series. Andretti in 2020 tried and failed to buy the existing Sauber team. From there, he applied for grid expansion and partnered with GM, the top-selling manufacturer in the United States. The inclusion of GM was championed by the FIA and president Mohammed Ben Sulayem, who said Michael Andretti’s application was the only one of seven applicants to meet all required criteria to expand F1’s current grid. “General Motors is a huge global brand and powerhouse in the OEM world and is working with impressive partners,” Ben Sulayem said Monday. “I am fully supportive of the efforts made by the FIA, Formula 1, GM and the team to maintain dialogue and work towards this outcome of an agreement in principle to progress this application.” Despite the FIA’s acceptance of Andretti and General Motors from the start, F1 wasn’t interested in Andretti — but did want GM. At one point, F1 asked GM to find another team to partner with besides Andretti. GM refused and F1 said it would revisit the Andretti application if and when Cadillac had an engine ready to compete. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. “Formula 1 has maintained a dialogue with General Motors, and its partners at TWG Global, regarding the viability of an entry following the commercial assessment and decision made by Formula 1 in January 2024,” F1 said in a statement. “Over the course of this year, they have achieved operational milestones and made clear their commitment to brand the 11th team GM/Cadillac, and that GM will enter as an engine supplier at a later time. Formula 1 is therefore pleased to move forward with this application process.” Yet another major shift in the debate over grid expansion occurred earlier this month with the announced resignation of Liberty Media CEO Greg Maffei, who was largely believed to be one of the biggest opponents of the Andretti entry. “With Formula 1’s continued growth plans in the US, we have always believed that welcoming an impressive US brand like GM/Cadillac to the grid and GM as a future power unit supplier could bring additional value and interest to the sport,” Maffei said. “We credit the leadership of General Motors and their partners with significant progress in their readiness to enter Formula 1.” ___ AP auto racing: https://apnews.com/hub/auto-racing Advertisement AdvertisementAn avoidable tragedy: On the Pushpa 2 stampedeFinancial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 13 unusual trades. Delving into the details, we found 38% of traders were bullish, while 53% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $257,880, and 10 were calls, valued at $538,961. Projected Price Targets Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $160.0 to $192.5 for AbbVie during the past quarter. Analyzing Volume & Open Interest Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AbbVie's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AbbVie's significant trades, within a strike price range of $160.0 to $192.5, over the past month. AbbVie Option Volume And Open Interest Over Last 30 Days Largest Options Trades Observed: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume ABBV PUT TRADE BULLISH 03/21/25 $6.55 $6.3 $6.3 $175.00 $189.0K 689 319 ABBV CALL TRADE BEARISH 01/17/25 $14.95 $14.2 $14.2 $165.00 $142.0K 4.0K 107 ABBV CALL SWEEP BEARISH 01/16/26 $26.75 $26.4 $26.4 $165.00 $124.0K 490 47 ABBV CALL TRADE BEARISH 12/20/24 $1.92 $1.78 $1.8 $185.00 $54.0K 3.6K 695 ABBV CALL SWEEP BEARISH 12/20/24 $3.8 $3.7 $3.7 $180.00 $36.6K 4.7K 328 About AbbVie AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). AbbVie's Current Market Status With a trading volume of 3,563,685, the price of ABBV is up by 0.2%, reaching $177.31. Current RSI values indicate that the stock is is currently neutral between overbought and oversold. Next earnings report is scheduled for 67 days from now. Unusual Options Activity Detected: Smart Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access . Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with Benzinga Pro for real-time alerts. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

As session ends, Congress looks to clean up loose ends

Microsoft's standard routine has it announcing new waves of Xbox Game Pass titles on the first and second Tuesdays of every month. However, when it is bringing a game from its Activision-Blizzard library over to Game Pass, a separate announcement goes up ahead of a wave. The last time this happened was in November when the company was bringing over for the subscription service. Today, the official Xbox social media account that is coming to Xbox Game Pass on December 4. The post even includes a short video with the game's starting signal lights going green for Game Pass: Start your engines and get ready to race in 3...2...1... CRASH TEAM RACING NITRO-FUELED IS COMING TO DECEMBER 4! 🏎️ 💨 is a remaster of the classic kart racer that was released in 1999. The original was developed by Naughty Dog for the PlayStation, but the remaster is by Beenox, who brought the title to Xbox One, PlayStation 4, and Nintendo Switch in 2019. In multiplayer, the game supports local play with up to four players, while multiplayer can have up to eight players racing with support for matchmaking. The original game's game modes, characters, tracks, power-ups, weapons, and controls are all here as well. The remaster even brings back the original racer's single-player adventure mode. It has players going up against the Nitros Oxide alien to save Earth. The remaster touts optional customization options that let players switch up the characters and the kart looks. As for characters, the remaster touts 56 of them to race with, bringing in content from Crash Nitro Kart and Crash Tag Team Racing. The classic boosting and reserve systems return but with some added enhancements for modern systems, including a power-slide function similar to other kart racers. The complete Xbox Game Pass wave announcement should also go live tomorrow, December 3, which will include many more games than just .

Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. Study published in Nephrology Dialysis Transplantation IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., OCX , a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraftTM, which was published in the journal, Nephrology Dialysis Transplantation. VitaGraft KidneyTM quantifies the amount of DNA fragments in transplant patients' blood that originate from the donor organ, a key biomarker for assessing graft health. This process is commonly referred to as donor-derived cell-free DNA (dd-cfDNA) testing and is widely used in clinical practice today. In this latest study, Oncocyte's proprietary diagnostic dd-cfDNA test using digital PCR was able to diagnose antibody-mediated rejection (AMR) in kidney transplant recipients nearly a year ahead of standard protocols 1 . "We are excited to see our dd-cfDNA technology demonstrate strong predictive value for AMR, supporting clinicians in identifying AMR in patients sooner, thereby enhancing the opportunity for better outcomes," said Oncocyte Chief Science Officer Dr. Ekkehard Schuetz. "The trial's results further validate dd-cfDNA as a critical biomarker that can bridge diagnostic gaps for transplant patients." For further context, de-novo donor specific antibody (dnDSA) is a routine biomarker used in kidney transplant management. The appearance of dnDSA in a patient -- that is, the patient is found to be dnDSA-positive (dnDSA+) -- signals an increased risk of AMR. This latest study shows that compared to standard of care, VitaGraft Kidney can significantly reduce the time to diagnosis of AMR in dnDSA+ patients. It is also the first randomized interventional study to validate any dd-cfDNA technology as a rule-in test for biopsy in a high-risk population. Catching AMR early, when kidney graft loss can be minimized, is becoming increasingly important as physicians explore the use of drugs, including the anti-CD38 drugs felzartamab and daratumumab, to manage rejection. Monitoring with VitaGraft in this high-risk patient population could support early intervention with these new therapeutic options. Once patients are on therapy, monitoring for therapeutic efficacy is also important to manage potential unwanted side effects. Publications using VitaGraft to monitor for efficacy for both aforementioned drugs can be found in the New England Journal of Medicine and Transplant International . In addition, earlier this year, Oncocyte signed an agreement with a European biotechnology company to be the provider of dd-cfDNA testing for a Phase II clinical trial for a separate therapeutic in AMR. Oncocyte expects to submit for claims expansion to its payor, MolDX 2 , to support the use of VitaGraft for these high-risk patients in the clinic. If granted, it would expand the use case beyond the current for-cause claim, opening significant new revenue opportunities. In sum, this clinical trial provides compelling evidence for dd-cfDNA monitoring as a tool for enhancing early intervention and improving outcomes for patients at increased risk of transplant rejection. Oncocyte scientists and inventors of the technology, Dr. Schuetz, Julia Beck and Kirsten Bornemann-Kolatzki, co-authored the study, which was initiated by researchers at Charité – Universitätsmedizin Berlin under the leadership of Prof. Klemens Budde. The study was published in Nephrology Dialysis Transplantation: Oxford Academic and may be found by accessing this link. Additional study details: Highlighting potential for improved patient outcomes, as well as implications for broader clinical applications and future therapies The interventional randomized trial, conducted between June 2021 and July 2023, involved 40 kidney transplant recipients with dnDSA, assessing longitudinal dd-cfDNA monitoring as a guiding tool for diagnostic biopsy compared to standard clinical practices. Oncocyte's proprietary dd-cfDNA technology was able to detect the onset of AMR significantly earlier in patients by guiding the indication for biopsy (median time from inclusion to diagnosis: 2.8 months) compared to the control group using standard of care (14.5 months). As noted above, this early intervention could offer a valuable advantage in transplant care by enabling prompt treatment before irreversible damage occurs. "This study underscores the impact of dd-cfDNA as a critical biomarker for early AMR detection, providing healthcare teams with timely data enabling them to initiate treatments sooner," said Dr. Aylin Akifova, first author from Charité. This study also suggests that dd-cfDNA monitoring could also be instrumental in identifying subclinical AMR—a silent condition that, if undiagnosed, can lead to significant graft damage. Additionally, the findings come at a crucial time, as mentioned above, as promising new treatments, including CD38-targeted therapies, are showing unprecedented efficacy in treating AMR. Early diagnosis with dd-cfDNA could provide the earliest window for intervention, offering an advantage for patients suffering from AMR, a disease with historically very limited treatment options. "We congratulate Charité's research teams on these compelling findings, which further underscore our mission to empower clinicians with tools for precision diagnostics while also democratizing access to novel molecular diagnostic testing to improve patient outcomes," said Josh Riggs, CEO of Oncocyte. "We look forward to expanding the clinical applications of dd-cfDNA technology and supporting transplant communities worldwide with our innovative diagnostic solutions." About Oncocyte Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft LiverTM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 jramson@pcgadvisory.com Forward-Looking Statements Any statements that are not historical fact (including but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the expectation that Oncocyte will submit for claims expansion to MolDX to support the use of VitaGraft for high-risk patients in the clinic, which may expand the use case and open significant new revenue opportunities, the company's anticipated expansion of clinical applications of dd-cfDNA technology, the company's goal to support transplant communities worldwide with its innovative diagnostic solutions, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Police hunt for UnitedHealthcare CEO's masked killer after 'brazen, targeted' attack on NYC street NEW YORK (AP) — A gunman killed UnitedHealthcare’s CEO on Wednesday in a “brazen, targeted attack” outside a Manhattan hotel where the health insurer was holding its investor conference, police said, setting off a massive search for the fleeing assailant hours before the annual Rockefeller Center Christmas tree lighting nearby. Brian Thompson, 50, was shot around 6:45 a.m. as he walked alone to the New York Hilton Midtown from a nearby hotel, police said. The shooter appeared to be “lying in wait for several minutes” before approaching Thompson from behind and opening fire, New York City Police Commissioner Jessica Tisch said. Police had not yet established a motive. “Many people passed the suspect, but he appeared to wait for his intended target,” Tisch said, adding that the shooting "does not appear to be a random act of violence.” Surveillance video reviewed by investigators shows someone emerging from behind a parked car, pointing a gun at Thompson’s back, then firing multiple times from several feet away. The gunman continues firing, interrupted by a brief gun jam, as Thompson stumbles forward and falls to the sidewalk. He then walks past Thompson and out of the frame. “From watching the video, it does seem that he’s proficient in the use of firearms as he was able to clear the malfunctions pretty quickly,” NYPD Chief of Detectives Joseph Kenny said. ___ UnitedHealthcare CEO kept a low public profile. Then he was shot to death in New York NEW YORK (AP) — Brian Thompson led one of the biggest health insurers in the U.S. but was unknown to millions of people his decisions affected. Then Wednesday's targeted fatal shooting of the UnitedHealthcare CEO on a midtown Manhattan sidewalk thrust the executive and his business into the national spotlight. Thompson, who was 50, had worked at the giant UnitedHealth Group Inc for 20 years and run the insurance arm since 2021 after running its Medicare and retirement business. As CEO, Thompson led a firm that provides health coverage to more than 49 million Americans — more than the population of Spain. United is the largest provider of Medicare Advantage plans, the privately run versions of the U.S. government’s Medicare program for people age 65 and older. The company also sells individual insurance and administers health-insurance coverage for thousands of employers and state-and federally funded Medicaid programs. The business run by Thompson brought in $281 billion in revenue last year, making it the largest subsidiary of the Minnetonka, Minnesota-based UnitedHealth Group. His $10.2 million annual pay package, including salary, bonus and stock options awards, made him one of the company's highest-paid executives. ___ Hegseth fights to save Pentagon nomination as sources say Trump considers DeSantis WASHINGTON (AP) — A defiant Pete Hegseth fought to save his nomination to be Donald Trump's defense secretary Wednesday as the president-elect considered possible replacements in the face of growing questions about the former Fox News host's personal conduct and ability to win Senate confirmation. Hegseth met with legislators on Capitol Hill, conducted a radio interview and released an opinion article denying allegations of sexual assault and excessive drinking. He insisted he was “not backing down one bit," that Trump was still supporting him and he planned to return Thursday for more meetings with lawmakers. But the president-elect's team was looking at alternatives including Florida Gov. Ron DeSantis. Trump himself remained quiet about Hegseth while issuing a flurry of statements on social media Wednesday about other nominees and his news coverage. Hegeth, asked if he'd meet with Trump on Thursday, said he'd meet with him “anytime he'd like." Hegseth is the latest nominee-designate to be imperiled by personal baggage after the recent withdrawal of Trump’s initial pick for attorney general, former Rep. Matt Gaetz, whose vulnerabilities were well-documented. But Hegseth’s past, including the revelation that he made a settlement payment after being accused of a sexual assault that he denies, was not widely known. ___ Supreme Court seems likely to uphold Tennessee's ban on medical treatments for transgender minors WASHINGTON (AP) — Hearing a high-profile culture-war clash, the Supreme Court on Wednesday seemed likely to uphold Tennessee's ban on gender-affirming care for minors. The justices’ decision, not expected for several months, could affect similar laws enacted by another 25 states and a range of other efforts to regulate the lives of transgender people, including which sports competitions they can join and which bathrooms they can use. The case is being weighed by a conservative-dominated court after a presidential election in which Donald Trump and his allies promised to roll back protections for transgender people, showcasing the uneasy intersection between law, politics and individual rights. The Biden administration's top Supreme Court lawyer warned a decision favorable to Tennessee also could be used to justify nationwide restrictions on transgender healthcare for minors. In arguments that lasted more than two hours, five of the six conservative justices voiced varying degrees of skepticism of arguments made by the administration and Chase Strangio, the ACLU lawyer for Tennessee families challenging the ban. ___ Peter Navarro served prison time related to Jan. 6. Now Trump is bringing him back as an adviser WASHINGTON (AP) — Former White House adviser Peter Navarro, who served prison time related to the Jan. 6 attack on the U.S. Capitol, will return to serve in Donald Trump’s second administration, the president-elect announced Wednesday. Navarro, a trade adviser during Trump’s first term, will be a senior counselor for trade and manufacturing, Trump said on Truth Social. The position, Trump wrote, “leverages Peter’s broad range of White House experience, while harnessing his extensive Policy analytic and Media skills.” The appointment was only the first in a flurry of announcements that Trump made on Wednesday as his presidential transition faced controversy over Pete Hegseth, Trump’s choice for Pentagon chief. Hegseth faces allegations of sexual misconduct, excessive drinking and financial mismanagement, and Trump has considered replacing him with another potential nominee. As he works to fill out his team, Trump said he wanted Paul Atkins, a financial industry veteran and an advocate for cryptocurrency, to serve as the next chairman of the Securities and Exchange Commission. He wrote on Truth Social that Atkins “recognizes that digital assets & other innovations are crucial to Making America Greater than Ever Before.” Trump also said he was changing course on his choice for White House counsel. He said his original pick, William McGinley, will work with the Department of Government Efficiency, which will be run by Elon Musk and Vivek Ramaswamy with the goal of cutting federal spending. Now David Warrington, who has worked as Trump’s personal lawyer and a lawyer for his campaign, will serve as White House counsel. ___ Israeli strikes on a Gaza tent camp kill at least 21 people, hospital says KHAN YOUNIS, Gaza Strip (AP) — Israeli airstrikes tore through a tent camp for displaced Palestinians in southern Gaza on Wednesday, sparking fires and killing at least 21 people, according to the head of a nearby hospital, in the latest assault on a sprawling tent city that Israel designated a humanitarian safe zone but has repeatedly targeted. The Israeli military said it struck senior Hamas militants “involved in terrorist activities” in the area, without providing additional details, and said it took precautions to minimize harm to civilians. The strike on the Muwasi tent camp was one of several deadly assaults across the Gaza Strip on Wednesday. An Israeli attack in central Gaza killed at least 10 more people, including four children, according to Palestinian medics. Israel’s devastating war in Gaza, launched after Hamas’ October 2023 attack, shows no signs of ending after nearly 14 months. Hamas is still holding dozens of Israeli hostages, and most of Gaza’s population has been displaced and is reliant on international food aid to survive. Israel is also pressing a major offensive in the isolated north, where experts say Palestinians might be experiencing famine. The Biden administration has pledged to make a new push for a Gaza ceasefire now that there's a truce in Lebanon between Israel and the militant group Hezbollah, ending more than a year of cross-border fighting. Meanwhile, President-elect Donald Trump demanded this week the release of hostages held by Hamas before he is sworn into office in January. ___ South Korean President Yoon's martial law declaration raises questions over his political future SEOUL, South Korea (AP) — President Yoon Suk Yeol’s stunning martial law declaration lasted just hours, but experts say it raised serious questions about his ability to govern for the remaining 2 1/2 years of his term and whether he will abide by democratic principles. The opposition-controlled parliament overturned the edict, and his rivals on Wednesday took steps to impeach him. One analyst called his action “political suicide.” Yoon’s political fate may depend on whether a large number of people in coming days take to the streets to push for his ouster. Here's a look at the political firestorm caused by the martial law declaration, the first of its kind in more than 40 years. Yoon's declaration of emergency martial law on Tuesday night was accompanied by a pledge to eliminate “shameless North Korea followers and anti-state forces at a single stroke.” He vowed to protect the country from “falling into the depths of national ruin.” Yoon, a conservative, cited repeated attempts by his liberal rivals in control of parliament to impeach his top officials and curtail key parts of his budget bill for next year. ___ French lawmakers vote to oust prime minister in the first successful no-confidence vote since 1962 PARIS (AP) — France’s far-right and left-wing lawmakers joined together Wednesday in a historic no-confidence vote prompted by budget disputes that forces Prime Minister Michel Barnier and his Cabinet members to resign, a first since 1962. The National Assembly approved the motion by 331 votes. A minimum of 288 were needed. President Emmanuel Macron insisted he will serve the rest of his term until 2027. However, he will need to appoint a new prime minister for the second time after July’s legislative elections led to a deeply divided parliament. Macron will address the French on Thursday evening, his office said, without providing details. Barnier is expected to formally resign by then. A conservative appointed in September, Barnier becomes the shortest-serving prime minister in France’s modern Republic. ___ White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign WASHINGTON (AP) — A top White House official on Wednesday said at least eight U.S. telecom firms and dozens of nations have been impacted by a Chinese hacking campaign. Deputy national security adviser Anne Neuberger offered new details about the breadth of the sprawling Chinese hacking campaign that gave officials in Beijing access to private texts and phone conversations of an unknown number of Americans. Neuberger divulged the scope of the hack a day after the FBI and the Cybersecurity and Infrastructure Security Agency issued guidance intended to help root out the hackers and prevent similar cyberespionage in the future. White House officials cautioned that the number of telecommunication firms and countries impacted could still grow. The U.S. believes that the hackers were able to gain access to communications of senior U.S. government officials and prominent political figures through the hack, Neuberger said. “We don’t believe any classified communications has been compromised,” Neuberger added during a call with reporters. ___ Harris found success with women who have cats, but Trump got the dog owner vote: AP VoteCast WASHINGTON (AP) — The lead-up to the 2024 election was all about cat owners. But in the end, the dogs had their day. President-elect Donald Trump won slightly more than half of voters who own either cats or dogs, with a big assist from dog owners, according to AP VoteCast, a survey of more than 120,000 voters. Dog owners were much more likely to support the Republican over Democratic Vice President Kamala Harris. Cat owners were split between the two candidates. About two-thirds of voters said they own a dog or cat, but pet owners don't usually get much attention from politicians. This year, however, past comments by Trump's running mate, Ohio Sen. JD Vance, about “childless cat ladies” briefly became a campaign issue — and Taylor Swift signed her Instagram endorsement of Harris in September as “Taylor Swift Childless Cat Lady.” Harris did end up decisively winning support from women who owned a cat but not a dog. Still, those voters were a relatively small slice of the electorate, and pet owners as a whole did not seem to hold Vance's remarks against the GOP ticket. Childless or not, women who only owned a cat were more likely to support Harris than were dog owners, or voters who had a cat and a dog. About 6 in 10 women who owned a cat but not a dog supported Harris, according to AP VoteCast. She did similarly well among women who did not own either kind of pet. The Associated Press

Oklahoma QB Jackson Arnold to Enter Transfer Portal, Expected to Attract Significant InterestFormula 1 expands grid to add General Motors’ Cadillac brand and new American team for 2026 season